A5014065333- Pain Management and Opioid Use
- Opioid Use Disorder Treatment
- Pain Mechanisms and Treatments
- Musculoskeletal pain and rehabilitation
- Pharmaceutical studies and practices
- Food Allergy and Anaphylaxis Research
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical Practices and Patient Outcomes
- Pain Management and Placebo Effect
- Child Nutrition and Feeding Issues
- Infant Nutrition and Health
- BRCA gene mutations in cancer
- Eosinophilic Esophagitis
- Pharmacogenetics and Drug Metabolism
- European Cultural and National Identity
- Clinical Nutrition and Gastroenterology
- Medieval Architecture and Archaeology
- Attention Deficit Hyperactivity Disorder
- Autism Spectrum Disorder Research
- Pharmacology and Obesity Treatment
Universitat de Miguel Hernández d'Elx
2018-2025
Instituto de investigación sanitaria y biomédica de Alicante
2022-2024
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2022-2024
Introduction: Opioid deprescription is the process of supervised tapering and safe withdrawal when a potentially inappropriate use detected. This represents challenge in chronic non-cancer pain (CNCP) patients who may respond differently to procedure. Our aim was analyze potential impact CYP2D6 phenotypes sex on clinical safety outcomes during an opioid disorder (OUD) process. Methods: A prospective observational study conducted CNCP ambulatory OUD (cases, n = 138) underwent 6-month dose...
The threats involved in the long-term opioid treatment of chronic non-cancer pain (CNCP) have increased notably. Strategies to identify at-risk patients are important because there is no clear evidence showing which screening or deprescription programmes appropriate. Our aim was evaluate provided by pharmacogenetics applied predict an analgesic toxicity profile prescription use disorder (POUD) participating programme. Pharmacogenetic markers were analysed observational, prospective programme...
Purpose: Given the number of people who suffer from chronic pain and impact on healthcare resources, it is imperative that with receive an appropriate matched treatment due stratified care. The aim this study was to characterize non-cancer (CNCP) patients' states, through unsupervised cluster analysis, implement clinical recommendations in Patients Methods: Real-world ambulatory CNCP cohort patients (n = 418) completed a multidimensional patient-reported registry, as part routine initial...
Abstract Tapentadol (TAP) and oxycodone/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness security daily practice, together with the influence of pharmacogenetic markers. An observational study developed ambulatory test cases under TAP (n = 194) or OXN 175) prescription controls (prescribed other opioids (control), n 216) CNCP patients. Pain intensity relief,...
Objective: To quantify patients' pain more objectively is essential to guide an individualized therapy, all the so in patients under long-term opioid-use. Only a thoughtful and objective understanding of risks benefits could improve standard care. Our aim was assess metric reliability validity integrated self-report Global Pain Status questionnaire impact on patient's health precise manner.
Despite the large body of research on sex differences in pain, there is a lack translation to real-world pain management. Our aim was analyse analgesic response oxycodone/naloxone (OXN) and tapentadol (TAP), comparison with other opioids (OPO) commonly prescribed for chronic non-cancer (CNCP). An observational cross-sectional study conducted ambulatory CNCP patients (n = 571). Sociodemographic, clinical (pain intensity, relief, quality life), safety (adverse events (AEs), adverse drug...
More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive withdrawal supported by rotation to buprenorphine and/or tramadol. The aim this research is analyse the long-term effectiveness deprescription taking into account impact sex and pharmacogenetics on inter-individual variability. A cross-sectional study was carried out from October 2019 June 2020 CNCP who had previously undergone an (n = 119 patients). Demographic,...
Rationale aims and objectivesː A good therapeutic alliance or relationship is relevant for healthcare providers exposed to patients’ suffering, especially when patients physicians may understand the painful experience differently. Our aim was explore impact of on analgesic outcomes in a real-world Pain Unit. Methodː cross-sectional observational study conducted ambulatory (n=69) who use pain killers long-term during treatment chronic non-cancer pain. Responses patient-doctor questionnaire...
Background and purpose: Tapentadol (TAP) oxycodone/naloxone (OXN) are available formulations that potentially offer improved gastrointestinal tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. The aim is to analyse their benefit/risk profiles the influence of pharmacogenetic markers daily practice. Experimental approach: A prospective, controlled study was developed with ambulatory CNCP patients. Cases were treated TAP (n=204) or OXN (n=180)...
Abstract A good therapeutic alliance is relevant for healthcare providers exposed to patients’ suffering, especially since patients and physicians may understand the painful experience differently. Our aim was explore impact of on analgesic outcomes in a real-world interdisciplinary pain unit (PU). cross-sectional observational study conducted outpatients ( n = 69) using opioids long-term basis treatment chronic non-cancer pain, where clinical pharmacologists pharmacists advised about their...
The long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 (CYP) 2D6, especially its extreme phenotypes, could help prevent drug-related adverse reactions or events (AEs). There are several warranting CYP2D6 screening that consumed by people with ASD, such as risperidone aripiprazole name few. A naturalistic...